Ventracor raises Aus$34 million for LVAD (left ventricular assist device) development:
This article was originally published in Clinica
Sydney, Australia firm Ventracor has raised Aus$33.75m (US$21.6m) to help fund trials of its left ventricular assist device (LVAD), VentrAssist. The company, which had existing cash of Aus$10.5m, says the financing will cover the completion of its 10-patient Australian pilot trial and enable it to begin a global pivotal trial in early 2004. The first patient to be implanted with the VentrAssist device received it on June 28 2003 (see Clinica No 1071, p 18) and was discharged on August 19, Ventracor said. A second patient will be implanted shortly, it added.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.